Scalper1 News
Biotech Receptos (RCPT) shot up more than 14% in morning trading on the stock market today, just shy of an all-time high, after it released more good data from a mid-stage clinical trial of its multiple-sclerosis drug. Receptos filed a late-breaking abstract on the study of RPC1063 for the MS Boston conference on multiple sclerosis, which runs Wednesday through Sunday. It already revealed its initial findings on June 10, showing an 86% reduction Scalper1 News
Scalper1 News